| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Outline of Final Research Achievements |
Abnormalities in O-mannosyl glycan cause a group of congenital muscular dystrophies known as dystroglycanopathies. We have identified complete structure of core M3 O-mannosyl glycan. It is a novel structure in mammals containing a newly identified glycan component, ribitol-5-phosphate. In this study, I revealed functions of gene products responsible for dystroglycanopathy, POMGNT1, FKTN, FKRP, and TMEM5. The results are significant findings related to investigation of comprehensive understanding of biosynthetic mechanisms of core M3 glycan. The discovery of new glycan structures and the identification of highly regulated mechanisms of glycan processing will help researchers to understand glycan functions and develop therapeutic strategies for dystroglycanopathies.
|
